FR09C0037I1 - - Google Patents

Info

Publication number
FR09C0037I1
FR09C0037I1 FR09C0037C FR09C0037I1 FR 09C0037 I1 FR09C0037 I1 FR 09C0037I1 FR 09C0037 C FR09C0037 C FR 09C0037C FR 09C0037 I1 FR09C0037 I1 FR 09C0037I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR09C0037I1 publication Critical patent/FR09C0037I1/fr
Application granted granted Critical
Publication of FR09C0037I2 publication Critical patent/FR09C0037I2/fr
Active legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151Methods of production or purification of viral material
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR09C0037C 1997-08-28 2009-08-14 Virus de l'encephalite japonaise attenue, adapte a des cellules vero et vaccin contre l'encephalite japonaise Active FR09C0037I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR19970042001 1997-08-28
KR19970042002 1997-08-28
PCT/KR1998/000259 WO1999011762A1 (en) 1997-08-28 1998-08-25 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine

Publications (2)

Publication Number Publication Date
FR09C0037I1 true FR09C0037I1 (de) 2009-09-25
FR09C0037I2 FR09C0037I2 (fr) 2021-11-05

Family

ID=26633032

Family Applications (1)

Application Number Title Priority Date Filing Date
FR09C0037C Active FR09C0037I2 (fr) 1997-08-28 2009-08-14 Virus de l'encephalite japonaise attenue, adapte a des cellules vero et vaccin contre l'encephalite japonaise

Country Status (15)

Country Link
US (1) US6309650B1 (de)
EP (2) EP1604685B1 (de)
JP (1) JP4161017B2 (de)
KR (1) KR100314404B1 (de)
CN (1) CN1142271C (de)
AU (1) AU748730B2 (de)
CA (1) CA2301000C (de)
DE (2) DE122009000037I2 (de)
DK (2) DK1025209T3 (de)
ES (2) ES2281929T3 (de)
FR (1) FR09C0037I2 (de)
MY (1) MY129773A (de)
NL (1) NL300391I2 (de)
NZ (1) NZ503522A (de)
WO (1) WO1999011762A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000083657A (ja) * 1998-07-13 2000-03-28 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスワクチン
KR20010032699A (ko) 1998-10-05 2001-04-25 무따이 마사히꼬 일본 뇌염 바이러스 감염에 대한 불활성 백신을 위한증강된 면역원 및 그 제조방법
ES2348159T3 (es) * 1999-04-22 2010-11-30 United States Department Of Agriculture Vacuna contra el sindrome respiratorio y reproductivo porcino basada en el aislado ja-142.
AU4472801A (en) * 2000-04-07 2001-10-23 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Inactivated japanese B encephalitis vaccine and process for producing the same
EP1416986A4 (de) * 2001-06-29 2005-12-14 Becton Dickinson Co Intradermale freisetzung von vakzinen und gentherapeutischen mitteln mit einer mikrokanüle
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
ES2329607T3 (es) * 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
CN100340596C (zh) * 2004-05-20 2007-10-03 佛山市顺德区汉达精密电子科技有限公司 回收聚碳酸酯/丙烯腈-丁二烯-苯乙烯共聚物及其回收方法
ATE412737T1 (de) * 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
CA2676775A1 (en) * 2007-01-31 2008-09-25 Sanofi Pasteur Biologics Co. Flavivirus vaccine vector against influenza virus
US9453055B2 (en) 2007-12-26 2016-09-27 Kitasato Daiichi Sankyo Vaccine Co., Ltd. Method of producing japanese encephalitis vaccine stably storable over long time and use of the vaccine
EP2298344B1 (de) * 2008-06-04 2016-08-17 The Chemo-Sero-Therapeutic Research Institute Verwendung von inaktivierten japanischen enzephalitis-virus-partikel als adjuvans
WO2010013601A1 (ja) * 2008-07-30 2010-02-04 久光製薬株式会社 マイクロニードルデバイスおよびマイクロニードルデバイスによる日本脳炎ウイルス抗原の奏功性を上昇させる方法
WO2010137036A2 (en) * 2009-05-25 2010-12-02 Panacea Biotec Ltd Novel japanese encephalitis vaccine and method of manufacturing the same
KR101144993B1 (ko) * 2009-06-18 2012-06-27 대한민국 돼지 일본뇌염 바이러스의 고농축 혈구응집용 항원
DK2788023T3 (en) 2011-12-06 2016-12-19 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
IN2013CH04135A (de) * 2013-09-14 2015-08-14 Bharat Biotech Int Ltd
CN105695424B (zh) * 2015-04-01 2019-06-14 中国食品药品检定研究院 乙型脑炎减毒活疫苗株sa14-14-2在人二倍体细胞2bs上的适应株及其疫苗
CA3009278A1 (en) * 2015-12-23 2017-06-29 Valneva Austria Gmbh Zika virus vaccine
JP6941566B2 (ja) * 2016-01-15 2021-09-29 Kmバイオロジクス株式会社 固定化ウイルス粒子を含むワクチン
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
KR20200056982A (ko) 2017-09-21 2020-05-25 발네바 에스이 면역원성 치쿤구니야 바이러스 chikv-델타5nsp3을 포함하는 약제학적 조성물의 생산 방법
US11648304B2 (en) 2017-11-03 2023-05-16 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
CA3084605A1 (en) 2017-11-30 2019-06-06 Takeda Vaccines, Inc. Method for inactivating zika virus and related methods
CN110684747B (zh) * 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
WO2020045368A1 (ja) * 2018-08-27 2020-03-05 マイキャン・テクノロジーズ株式会社 不死化単球細胞および誘導細胞を用いた抗感染症薬,ワクチンなどの評価方法
IL296071A (en) 2020-03-01 2022-11-01 Valneva Austria Gmbh Sars-cov-2 virus vaccine with adjuvant cytidine-phosphoguanosine
EP3895729A1 (de) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanter sars-cov-2-virus-impfstoff
WO2021204825A2 (en) 2020-04-06 2021-10-14 Valneva Austria Gmbh INACTIVATED SARS-CoV-2 VIRUS VACCINE
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
WO2024153686A1 (en) 2023-01-18 2024-07-25 Valneva Austria Gmbh Process for virus production in a bioreactor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2704258B2 (ja) * 1987-10-31 1998-01-26 日本臓器製薬株式会社 組み換えワクチニアウイルス
GB8821656D0 (en) * 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect
JPH085803B2 (ja) * 1988-11-10 1996-01-24 武田薬品工業株式会社 日本脳炎ワクチンの製造法
EP0562136A1 (de) * 1992-03-24 1993-09-29 Division Of Microbiology, Kyoto Biken Laboratories, Inc. Lebender Impfstoff gegen Getah Virus infektiöse Krankheiten, und dreiwertiger lebender Impfstoff gegen japanische Enkephalitis Virus, Schweinparvovirus und Getah Virus
US6010894A (en) * 1997-06-13 2000-01-04 Research Development Foundation Method of screening for attenuating viruses

Also Published As

Publication number Publication date
NL300391I2 (nl) 2009-11-02
WO1999011762A1 (en) 1999-03-11
KR19990023955A (ko) 1999-03-25
EP1604685A3 (de) 2006-07-05
NZ503522A (en) 2001-06-29
CA2301000A1 (en) 1999-03-11
DE69837211D1 (de) 2007-04-12
AU748730B2 (en) 2002-06-13
DK1025209T3 (da) 2007-06-25
KR100314404B1 (ko) 2002-10-12
EP1025209B1 (de) 2007-02-28
NL300391I1 (nl) 2009-08-03
FR09C0037I2 (fr) 2021-11-05
EP1604685A2 (de) 2005-12-14
DE122009000037I2 (de) 2011-06-16
US6309650B1 (en) 2001-10-30
CN1142271C (zh) 2004-03-17
MY129773A (en) 2007-04-30
CN1272879A (zh) 2000-11-08
AU9004798A (en) 1999-03-22
EP1604685B1 (de) 2012-02-22
CA2301000C (en) 2003-07-08
EP1025209A1 (de) 2000-08-09
DE122009000037I1 (de) 2009-11-05
DE69837211T2 (de) 2007-12-06
ES2281929T3 (es) 2007-10-01
JP4161017B2 (ja) 2008-10-08
DK1604685T3 (da) 2012-06-18
ES2382946T3 (es) 2012-06-14
JP2001514844A (ja) 2001-09-18

Similar Documents

Publication Publication Date Title
FR07C0057I1 (de)
FR09C0037I1 (de)
CH0944937H2 (de)
ITMI971105A0 (de)
ITTO970118V0 (de)
ITMI970397V0 (de)
IN182159B (de)
ITFI970057A0 (de)
ITRM970369A0 (de)
ITMI970351V0 (de)
IN185786B (de)
CN3056251S (de)
CN3055713S (de)
CN3057229S (de)
CN3056875S (de)
CN3058923S (de)
CN3056826S (de)
CN3056811S (de)
CN3056419S (de)
CN3058984S (de)
CN3058000S (de)
CN3056418S (de)
CN3056417S (de)
CN3056276S (de)
CN3057613S (de)